Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11268140 | PMC |
| http://dx.doi.org/10.1503/cmaj.150837-l | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Acetaminophen as a cause of "non-acetaminophen-related acute liver failure".
CMAJ
July 2024
Clinical professor, School of Population and Public Health, University of British Columbia, Vancouver, BC.
Drug-Induced Liver Injury Secondary to Turmeric Use.
Eur J Case Rep Intern Med
April 2023
Department of Internal Medicine, Rutgers-Monmouth Medical Center, Long Branch, New Jersey, USA.
Unlabelled: Turmeric is a herbal medication and spice which has been used for thousands of years in traditional Eastern medicine for its flavour, colour, and purported anti-inflammatory, antioxidant, antineoplastic and antimicrobial properties. It has recently garnered interest and popularity worldwide for these reasons. While turmeric supplements are generally safe, some reports of toxicity are emerging.
View Article and Find Full Text PDFThe Role of Carbamoyl Phosphate Synthetase 1 as a Prognostic Biomarker in Patients With Acetaminophen-induced Acute Liver Failure.
Clin Gastroenterol Hepatol
November 2023
Robert Wood Johnson Medical School, Rutgers University, New Brunswick, NJ; Center for Advanced Biotechnology and Medicine, Rutgers University, Piscataway, NJ; Division of Gastroenterology and Hepatology, University of Michigan Medical School, Ann Arbor, MI; Department of Molecular and Integrative Physiology, University of Michigan Medical School, Ann Arbor, MI. Electronic address:
Background & Aims: Carbamoyl phosphate synthetase 1 (CPS1) is a highly abundant mitochondrial urea cycle enzyme that is expressed primarily in hepatocytes. CPS1 is constitutively and physiologically secreted into bile but is released into the bloodstream upon acute liver injury (ALI). Given its abundance and known short half-life, we tested the hypothesis that it may serve as a prognostic serum biomarker in the setting of acute liver failure (ALF).
View Article and Find Full Text PDFUse of Oral N-Acetylcysteine (NAC) in Non-Acetaminophen-Induced Acute Hepatic Failure.
Cureus
March 2023
Pharmacology, Pakistan Kidney and Liver Institute and Research Center, Lahore, PAK.
Background: Acute liver failure (ALF) is a syndrome rather than a specific disease with several possible causes, and viral hepatitis is a major cause. The objective of the study was to assess the benefit of N-acetylcysteine (NAC) in non-acetaminophen-induced acute liver failure (NAI-ALF).
Methods: A total of six patients with a diagnosis of acute liver failure (ALF) were included in the study.
Role of N-acetylcysteine in non-acetaminophen-related acute liver failure: an updated meta-analysis and systematic review.
Ann Gastroenterol
January 2021
Department of Gastroenterology and Hepatology (Saqib Walayat, Sonu Dhillon).
Background: The American Association for the Study of Liver Diseases recommends that N-acetylcysteine (NAC) may be beneficial in non-acetaminophen-related drug-induced liver injury. A subsequent review and analysis reported the current evidence to be inconclusive. Herein, we present an updated review and meta-analysis.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!